StreetInsider.com News Articles

Form 10-Q Apimeds Pharmaceuticals For: Mar 31

Tue, 26 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260526/26549867.html

Form 10-Q Apimeds Pharmaceuticals For: Mar 31

Tue, 26 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260526/26549867.html

Form NT 10-Q Apimeds Pharmaceuticals For: Mar 31

Fri, 15 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260515/26505127.html

Form NT 10-Q Apimeds Pharmaceuticals For: Mar 31

Fri, 15 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260515/26505127.html

Form SCHEDULE 13D/A Apimeds Pharmaceuticals Filed by: Inscobee Inc.

Thu, 07 May 2026 09:12:00 -0400

si-local-file:///var/storage/secattach/20260507/26449912.html

Form SCHEDULE 13D/A Apimeds Pharmaceuticals Filed by: Inscobee Inc.

Thu, 07 May 2026 09:12:00 -0400

si-local-file:///var/storage/secattach/20260507/26449912.html

Apimeds Pharma shares soar on Inscobee settlement

Tue, 05 May 2026 14:15:44 -0400

Investing.com -- Shares of Apimeds Pharma jumped over 20% before entering a volatility trading halt on Tuesday after the company announced a settlement with Inscobee Inc. and Apimeds Inc., resolving disputes from its December 1, 2025 merger with MindWave Innovations Inc.

The settlement enables completion of the merger transactions and the company's previously disclosed $100 million PIPE financing. APUS common stock is expected to resume trading on the NYSE American on Tuesday, subject to NYSE approval.

Under the settlement terms, the Inscobee parties confirmed that the Stockholder Support and Lock-Up Agreement and related voting agreements remain valid and binding. Prior written stockholder

Apimeds halted on volatility

Tue, 05 May 2026 14:08:25 -0400

Apimeds halted on volatility

Tue, 05 May 2026 14:08:25 -0400

Apimeds halted on volatility

Apimeds settles with Inscobee, clears path for merger and $100M financing

Tue, 05 May 2026 14:07:33 -0400

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a settlement with Inscobee Inc. and Apimeds Inc., resolving disputes from its December 1, 2025 merger with MindWave Innovations Inc.

The settlement enables completion of the merger transactions and a previously disclosed $100 million PIPE financing. APUS common stock is expected to resume trading on the NYSE American on Tuesday, May 5, 2026, subject to NYSE approval.

Under the agreement, the Inscobee parties confirmed that stockholder support and lock-up agreements remain valid, while prior written stockholder consents to remove company directors are void. Dr. Vin Menon continues as co-chief executive officer alongside Sungjoon Chae,

Apimeds settles with Inscobee, clears path for merger and $100M financing

Tue, 05 May 2026 14:07:33 -0400

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a settlement with Inscobee Inc. and Apimeds Inc., resolving disputes from its December 1, 2025 merger with MindWave Innovations Inc.

Apimeds settles with Inscobee, clears path for merger and $100M financing

Tue, 05 May 2026 14:07:33 -0400

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a settlement with Inscobee Inc. and Apimeds Inc., resolving disputes from its December 1, 2025 merger with MindWave Innovations Inc.

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program